Sensitizing multidrug-resistant leukemia cells to common cytostatics by an aluminium-salen complex that has high-apoptotic effects in leukemia, lymphoma and mamma carcinoma cells

Hopff, Sina M.; Onambele, Liliane A.; Brandenburg, Marc; Berkessel, Albrecht; Prokop, Aram

doi:10.1007/s10534-020-00273-x

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, research has focused on substances that selectively induce apoptosis in malignant cells and at low concentrations. We and others have reported on novel metal-based compounds that can overcome these resistances and have a low toxicity [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ]. Metal complexes have long been of big interest in modern cancer research [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro

Wilke

Burmeister

Frias

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Ruthenium(II) complexes with N-heterocyclic carbene (NHC) ligands have recently attracted attention as novel chemotherapeutic agents. The complex HB324 was intensively studied as an apoptosis-inducing compound in resistant cell lines. HB324 induced apoptosis via mitochondrial pathways. Of particular interest is the upregulation of the Harakiri resistance protein, which inhibits the anti-apoptotic and death repressor proteins Bcl-2 (B-cell lymphoma 2) and BCL-xL (B-cell lymphoma-extra large). Moreover, HB324 showed synergistic activity with various established anticancer drugs and overcame resistance in several cell lines, such as neuroblastoma cells. In conclusion, HB324 showed promising potential as a novel anticancer agent in vitro, suggesting further investigations on this and other preclinical ruthenium drug candidates.

show abstract